Scientists advising the government say a Pap test is a good way to screen young and middle-aged women for cervical cancer once every three years.
But they say there is not enough evidence yet to back testing for HPV, the virus that causes the disease.
That’s at odds with the American Cancer Society and other groups, which have long said both tests are an option for women over 30.
Those groups and the government advisory task force separately plan to release proposed guidelines for cervical cancer screening tomorrow and invite public comment.
The task force is the same group that recommended against routine PSA tests to screen for prostate cancer, saying they were doing more harm than good for men at average risk.
Cervical cancer screening is a success story. In the United States, cases and death rates have been cut more than in half since the 1970s because of Pap smears — lab exams of cells scraped from the cervix, the gateway to the uterus. The test can find early signs of this slow-growing cancer and treat them before a tumor develops.
So “the bar is set pretty high” for a test to replace or supplement Paps, said Dr. Evelyn Whitlock of Kaiser Permanente Northwest’s Center for Health Research in Portland, Ore.
Not enough is known about the benefits and especially the harms of HPV testing, concludes the scientific review she led that was published Monday. The task force that asked for the review voted unanimously in March that there was insufficient evidence to recommend for or against HPV testing, but has continued to discuss the issue and will give its advice tomorrow.
Here’s the dilemma: Infections with HPV, the human papillomavirus, are very common especially in young women. They usually go away on their own and only pose a cancer risk when they last a year or more.
Tests that find these infections might lead many women to more invasive follow-up tests that can weaken the cervix and cause problems having children later. No big studies measure these harms, and a test that flags more potential cancers might not be better.
“A lot of people use the word ‘superior’ to mean it catches more cancer. But the other side of it is, does it catch more things that are not cancer? You have to weigh benefits versus harms for any screening test,” said Debbie Saslow, the cancer society’s director of breast and gynecologic cancer.
The evidence review finds little risk of cervical cancer in women under 21 and says screening below that age may be harmful. It also says screening can stop at age 65 if a woman has had adequate screening in the past and is not at high risk.
The review was published Monday in the Annals of Internal Medicine.
The journal also published a study on breast cancer screening. That research supports mammograms every other year instead of annually. Over time, there are more false alarms with annual screening, and going every two years does not significantly raise the risk of a late-stage cancer being found, the report says.
Breast cancer screening has been an emotional issue since 2009 when the government task force said women at average risk don’t need mammograms until age 50 and then just every other year to age 74. The cancer society and others still advise annual tests starting at 40.
The federally funded study gives a real-world view of the downside of screening — the worry, expense, and risks of biopsies and other tests that ultimately prove unnecessary.
It looked at false alarms at various intervals of screening for nearly 170,000 women ages 40 to 59, plus nearly 4,500 other women with invasive breast cancer. About 61 percent of women who get a mammogram annually for a decade will be called back at least once for extra tests that turn out not to show breast cancer, the study found.
Guidelines: Please keep your comments smart and civil. Don't attack other readers personally, and keep your language decent. Comments that violate these standards, or our privacy statement or visitor's agreement, are subject to being removed and commenters are subject to being banned. To post comments, you must be a registered user on toledoblade.com. To find out more, please visit the FAQ.